JP Morgan Healthcare Conference Highlights
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” into making new molecules. - How NVIDIA…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →When the Government Becomes Your Co-investor
AI Leaders Want to Slow Down Development For…
Harvard's Judgment Professor: Why Numbers Don't Make Decisions, People Do
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Lots More on What's Hot at JPM's Health Conference
Nvidia’s Rough Week… And Why Users Start & Stop GLP-1 Drugs 1/31/25
Can a GLP-1 Pill Revive Novo Nordisk?
Longevity: Can We Add Another 30 Years? | The Decade Ahead
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.